Medicine Press release

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received orphan drug designation for anticancer agent the EZH2*1 inhibitor tazemetostat hydrobromide (genericname, product name "Tazverik(R) Tablets 200 mg", "tazemetostat") for unresectable INI1*2-negative epithelioid sarcoma that has progressed after chemotherapy, from the Ministry of Health, Labour and Welfare (MHLW).
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received orphan drug designation for anticancer agent the EZH2*1 inhibitor tazemetostat hydrobromide (genericname, product name "Tazverik(R) Tablets 200 mg", "tazemetostat") for unresectable INI1*2-negative epithelioid sarcoma that has progressed after chemotherapy, from the Ministry of Health, Labour and Welfare (MHLW).
More info..

Fujitsu today announced the development of a secure and efficient AI agent platform to accelerate operational efficiency and ensure stable medical service provision in Japan's healthcare sector.
More info..

Mitsubishi Corporation ("MC") is pleased to announce that it has completed its investment in Fullerton Health Pte. Ltd. ("Fullerton Health"), a leading Managed-Care* provider in Southeast Asia, as of 22 August, 2025.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the anti-amyloid beta (AB) monoclonal antibody "LEQEMBI(R)" has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the anti-amyloid beta (AB) monoclonal antibody "LEQEMBI(R)" has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the anti-amyloid beta (AB) monoclonal antibody "LEQEMBI(R)" has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025.
More info..

On April 21, 2025 (local time), the experimental unit was installed in the SpaceX CRS-32, an unmanned commercial resupply spacecraft to the International Space Station (ISS) launched from the Kennedy Space Center in the U.S.
More info..

NEC Corporation (NEC; TSE: 6701) today announced the signing of a Memorandum of Understanding (MOU) with the United Nations Population Fund (UNFPA) (*1), which promotes activities to protect the health and rights of women and girls, to collaborate on the development of a beneficiary information management system.
More info..

NEC Corporation (NEC; TSE: 6701) today announced the signing of a Memorandum of Understanding (MOU) with the United Nations Population Fund (UNFPA) (*1), which promotes activities to protect the health and rights of women and girls, to collaborate on the development of a beneficiary information management system.
More info..